Literature DB >> 872088

Pharmacokinetics of vindesine and vincristine in humans.

R J Owellen, M A Root, F O Hains.   

Abstract

Vindesine, a new Phase 1 Vinca alkaloid congener, exhibited serum pharmacokinetic behavior in humans compatible with a three-compartment, open mammilary model. The kinetic parameters included: t1/2 alpha=3.24+/-1.14 min, t1/2beta=99.0+/-44.5 min, t1/2gamma=1213+/-493 min, Vc (Valpha)=4.81+/-2.12 liters, Vbeta=58.2+/-50.5 liters, Vgamma=598+/-294 liters. Vincristine, studied only for the first 4 hr, behaved like a two-compartment system, with values of t1/2 alpha=3.37+/-0.72 min, t1/2beta=155+/-18 min, Valpha=4.53+/-0.49 liters, and Vbeta=57.3+/-21.1 liters. Urine excretion data demonstrated that most drug elimination occurred within the first 24 hr and amounted to 13.2+/-5.9% for vindesine and 9.5+/-5.1% for vincristine.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 872088

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  BubR1 is frequently repressed in acute myeloid leukemia and its re-expression sensitizes cells to antimitotic therapy.

Authors:  Dominik Schnerch; Andrea Schmidts; Marie Follo; Josefina Udi; Julia Felthaus; Dietmar Pfeifer; Monika Engelhardt; Ralph Wäsch
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

Review 2.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 3.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

4.  Vincristine infusion. A phase I study.

Authors:  W Weber; G A Nagel; E Nagel-Studer; R Albrecht
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

5.  Pharmacokinetics of vindesine bolus and infusion.

Authors:  D V Jackson; V S Sethi; T R Long; H B Muss; C L Spurr
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

6.  Clinical pharmacokinetics of vindesine.

Authors:  R L Nelson; R W Dyke; M A Root
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

7.  Antitubulin activity of vinblastine and vincristine. Clinical implications of the radial segmentation test.

Authors:  G Simmingsköld; B Norberg; A Norberg; U B Söderström
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

8.  Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice.

Authors:  James W Behan; Vassilios I Avramis; Jason P Yun; Stan G Louie; Steven D Mittelman
Journal:  Pharmacol Res       Date:  2010-01-18       Impact factor: 7.658

9.  Therapeutic efficacy and pharmacokinetics of vindesine and vindesine-cisplatin in previously treated patients with non-small cell lung carcinoma.

Authors:  J Z Fuks; M J Egorin; J Aisner; D A Van Echo; S Ostrow; N R Bachur; P H Wiernik
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

10.  Vincristine activates c-Jun N-terminal kinase in chronic lymphocytic leukaemia in vivo.

Authors:  Darcy J P Bates; Lionel D Lewis; Alan Eastman; Alexey V Danilov
Journal:  Br J Clin Pharmacol       Date:  2015-05-19       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.